FDA approved Morphine Sulfate Oral Solution for Acute and Chronic PainFDA approved new morphine liquid for severe pain in adults and children.

FDA From the archive Source published March 17, 2008 Summary added June 24, 2026 DOI ↗ Editorial oversight: Dr. Ji-eun Park, MD · Brain, Mind & Pain

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Consider reserving Morphine Sulfate Oral Solution for patients with severe pain unresponsive to alternatives, using lowest effective dose and shortest duration.

The FDA has approved Morphine Sulfate Oral Solution, an opioid agonist, for the management of acute and chronic pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. The approval covers two concentrations: 2 mg/mL and 4 mg/mL for adults and pediatric patients aged 2 years and older, and a 20 mg/mL concentration restricted to opioid-tolerant adult patients. Clinicians should note that the drug carries significant risks of addiction, abuse, and misuse, and should be reserved for patients who have not tolerated or achieved adequate analgesia with non-opioid alternatives or opioid combination products. The label emphasizes using the lowest effective dose for the shortest duration and considering naloxone co-prescribing for overdose risk. This approval provides an additional opioid formulation for pain management but reinforces the need for careful patient selection and monitoring.

＋ Clinical Details (Mechanism · Dosing · Trial Data · Warnings)

Mechanism of Action

Morphine Sulfate Oral Solution is an opioid agonist. The exact mechanism of action is not fully understood, but morphine is known to bind to opioid receptors in the central nervous system, producing analgesia.

Indication & Patient Population

Morphine Sulfate Oral Solution 2 mg/mL and 4 mg/mL is indicated for the management of acute and chronic pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate in adults and pediatric patients 2 years of age and older. Morphine Sulfate Oral Solution 20 mg/mL is indicated for the relief of acute and chronic pain in opioid-tolerant adult patients. Because of the risks of addiction, abuse, and misuse, reserve for patients who have not tolerated or achieved adequate analgesia with alternative treatments. Do not use for extended periods unless pain remains severe and alternatives inadequate.

Dosing & Administration

Use the lowest effective dose for the shortest duration. For adults, initiate with 10 to 20 mg every 4 hours as needed. For pediatric patients 2 years and older, initiate with 0.15 mg/kg to 0.3 mg/kg every 4 hours as needed, not to exceed 20 mg. The 20 mg/mL concentration is only for opioid-tolerant adults. Discuss naloxone availability with patients. Do not abruptly discontinue in physically dependent patients.

Key Clinical Trial Data

Trial data not available in label.

Warnings & Contraindications

Risks include addiction, abuse, misuse, respiratory depression, and neonatal opioid withdrawal syndrome. Contraindicated in patients with significant respiratory depression, acute or severe bronchial asthma, known or suspected gastrointestinal obstruction, and hypersensitivity to morphine. Use caution in patients with head injury, impaired consciousness, or conditions that increase intracranial pressure.

Place in Therapy

Morphine Sulfate Oral Solution is an opioid agonist indicated for pain severe enough to require an opioid when alternatives are inadequate. It should be reserved for patients who have not tolerated or achieved adequate analgesia with non-opioid analgesics or opioid combination products. The 20 mg/mL concentration is restricted to opioid-tolerant adults. Clinicians should carefully weigh risks and benefits, use the lowest effective dose, and consider naloxone co-prescribing.

The FDA has approved a new liquid morphine medicine called Morphine Sulfate Oral Solution. It is an opioid painkiller for severe pain that needs an opioid and has not been helped by other treatments. The approval covers two lower strengths (2 mg/mL and 4 mg/mL) for adults and children ages 2 and older, and a higher strength (20 mg/mL) only for adults who are already used to taking opioids.

This medicine is meant for people who have not gotten enough pain relief from non-opioid pain relievers or from opioid combination products. Because opioids can lead to addiction, abuse, and misuse, doctors are told to prescribe the lowest dose for the shortest time needed. The FDA also recommends that doctors consider prescribing naloxone along with this medicine to help reverse an overdose if it happens.

This approval gives doctors another tool to manage severe pain. However, it does not mean that opioids are safe for everyone. Patients should talk to their doctor about the risks and benefits of this medicine and ask about other options. It is important to use this drug exactly as prescribed and to store it safely away from children and others.

What this means for you:

This new morphine liquid is for severe pain when other treatments don't work, but it carries serious risks and must be used with caution.

Study Details

Study typeFda approval

PublishedMar 2008

View Original Abstract ↓

1 INDICATIONS AND USAGE Morphine Sulfate Oral Solution 2 mg/mL and 4 mg/mL is indicated for the management of: adults with acute and chronic pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. pediatric patients 2 years of age and older with acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Morphine Sulfate Oral Solution 20 mg/mL is indicated for the relief of acute and chronic pain in opioid-tolerant adult patients. Morphine Sulfate Oral Solution is an opioid agonist. Morphine Sulfate 2 mg/mL and 4 mg/mL is indicated for the management of: adults with acute and chronic pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. ( 1 ) pediatric patients 2 years of age and older with acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. ( 1 ) Morphine Sulfate Oral Solution 20 mg/mL is indicated for: the relief of acute and chronic pain in opioid-tolerant adult patients. ( 1 ) Limitations of Use ( 1 ): Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration ( 5.2 ), reserve Morphine Sulfate Oral Solution for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or opioid combination products): Have not been tolerated or are not expected to be tolerated Have not provided adequate analgesia or are not expected to provide adequate analgesia Morphine Sulfate Oral Solution should not be used for an extended period of time unless the pain remains severe enough to require an opioid analgesic and for which alternative treatment options continue to be inadequate. Limitations of Use: Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration [see Warnings and Precautions (5.2) ] , reserve Morphine Sulfate Oral Solution for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or opioid combination products): Have not been tolerated or are not expected to be tolerated, Have not provided adequate analgesia or are not expected to provide adequate analgesia. Morphine Sulfate Oral Solution should not be used for an extended period of time unless the pain remains severe enough to require an opioid analgesic and for which alternative treatment options continue to be inadequate.

FDA approved Morphine Sulfate Oral Solution for Acute and Chronic PainFDA approved new morphine liquid for severe pain in adults and children.

Study Details

Intravenous tenecteplase improves functional outcomes but increases hemorrhage risk in non-large vessel occlusion acute ischemic stroke

Tenecteplase improves stroke recovery but increases bleeding risk in late treatment window

Clinical research that matters. Delivered to your inbox.

FDA approved Morphine Sulfate Oral Solution for Acute and Chronic PainFDA approved new morphine liquid for severe pain in adults and children.

Study Details

Intravenous tenecteplase improves functional outcomes but increases hemorrhage risk in non-large vessel occlusion acute ischemic stroke

Tenecteplase improves stroke recovery but increases bleeding risk in late treatment window

Clinical research that matters. Delivered to your inbox.

Related in Neurology

From Other Specialties